High-dose cytarabin versus low-dose cytarabin plus interferon-alpha-2a both followed by maintenance with interferon-alpha-2a in chronic myeloid leukemia.
Completed
- Conditions
- Chronic myeloid leukemia.
- Registration Number
- NL-OMON27157
- Lead Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl
- Brief Summary
Ann Hematol. 2007 Feb;86(2):117-25. Epub 2006 Oct 10.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 102
Inclusion Criteria
1. Newly diagnosed patients with CML in first chronic phase <= 6 months;
2. Presence of Philadelphia chromosome or BCR/ABL rearrangement;
Exclusion Criteria
1. CML in blastic phase;
2. CML in accelerated phase;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Event-free survival.
- Secondary Outcome Measures
Name Time Method 1. Hematological and cytogenetical remission;<br /><br>2. Overall survival;<br /><br>3. Remission duration.